Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

Vtama is projected to contribute $150 million in 2025 revenue, supported by its new label approval for atopic dermatitis. Nexplanon is expected to reach at least $1 billion in revenue for 2025. Q4 ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Executive Director and Co-Founder of the Not-For-Profit U.S. Biosimilars Forum PBM reform did not make it into the final continuing resolution this past December. Now, time is of the essence for ...

Celltrion Inc.’s biosimilar versions of Amgen Inc.’s blockbuster bone-strengthening drugs Prolia and Xgeva are blocked in the US until June 1 as part of a settlement agreement, according to a filing ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52. Patients with psoriasis who switched ...

Known as AVT05, the Alvotech medication is a proposed biosimilar to Simponi, prescribed to treat various inflammatory conditions. The FDA is set to review the Biologics License Applications (BLAs) for ...

A majority of biosimilar gains are due to Hyrimoz (adalimumab-adaz) and Hadlima (adalimumab-bwwd). These biosimilars have provided the market with diverse WAC pricing options that offer reduced ...

In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...